We are live on ! Find out more

126 hedge funds and large institutions have $1.08B invested in Insmed in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 37 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 16

27% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 37

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

2% more funds holding

Funds holding: 123126 (+3)

1.69% more ownership

Funds ownership: 105.26%106.95% (+1.7%)

34% less capital invested

Capital invested by funds: $1.64B → $1.08B (-$557M)

73% less call options, than puts

Call options by funds: $6.26M | Put options by funds: $22.8M

Holders
126
Holders Change
+3
Holders Change %
+2.44%
% of All Funds
2.8%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
21
Increased
47
Reduced
37
Closed
16
Calls
$6.26M
Puts
$22.8M
Net Calls
-$16.5M
Net Calls Change
+$9.42M

INSM Hedge Fund Activity: Q4 2018 in Review

126 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q4 2018, worth a combined $1.08B — down 34% from $1.64B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new INSM positions and 16 closed out — a net gain of 5 holders — while 47 added to existing stakes and 37 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $33.8M. The largest seller was OrbiMed, exiting entirely with an estimated $37M sold.

  • 126 institutional investors held Insmed (INSM) as of Q4 2018, up from 123 in Q3 2018.
  • Funds reported $1.08B of Insmed stock for Q4 2018, down 34% quarter-over-quarter.
  • 21 funds opened new Insmed positions in Q4 2018 and 16 closed out, a net change of +5 holders.
  • The largest Insmed buyer in Q4 2018 was Janus Henderson Group, an estimated $33.8M added.
  • The largest Insmed seller in Q4 2018 was OrbiMed, an estimated $37M sold.

Based on aggregated 13F filings for Q4 2018.